Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence

Dear Editor, We would like to reply to “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11years: Correspondence” regarding our article entitled “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5–11years: Results from an active pharmacovigilan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ripabelli, Giancarlo, Salzo, Angelo, Tamburro, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980581/
https://www.ncbi.nlm.nih.gov/pubmed/36655383
http://dx.doi.org/10.1080/21645515.2023.2168947
_version_ 1784899929263570944
author Ripabelli, Giancarlo
Salzo, Angelo
Tamburro, Manuela
author_facet Ripabelli, Giancarlo
Salzo, Angelo
Tamburro, Manuela
author_sort Ripabelli, Giancarlo
collection PubMed
description Dear Editor, We would like to reply to “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11years: Correspondence” regarding our article entitled “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5–11years: Results from an active pharmacovigilance study in central Italy.”
format Online
Article
Text
id pubmed-9980581
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-99805812023-03-03 Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence Ripabelli, Giancarlo Salzo, Angelo Tamburro, Manuela Hum Vaccin Immunother Coronavirus Dear Editor, We would like to reply to “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11years: Correspondence” regarding our article entitled “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5–11years: Results from an active pharmacovigilance study in central Italy.” Taylor & Francis 2023-01-19 /pmc/articles/PMC9980581/ /pubmed/36655383 http://dx.doi.org/10.1080/21645515.2023.2168947 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Coronavirus
Ripabelli, Giancarlo
Salzo, Angelo
Tamburro, Manuela
Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
title Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
title_full Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
title_fullStr Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
title_full_unstemmed Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
title_short Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
title_sort safety of mrna bnt162b2 covid-19 (pfizer-biontech) vaccine in children aged 5–11 years: author’s reply to correspondence
topic Coronavirus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980581/
https://www.ncbi.nlm.nih.gov/pubmed/36655383
http://dx.doi.org/10.1080/21645515.2023.2168947
work_keys_str_mv AT ripabelligiancarlo safetyofmrnabnt162b2covid19pfizerbiontechvaccineinchildrenaged511yearsauthorsreplytocorrespondence
AT salzoangelo safetyofmrnabnt162b2covid19pfizerbiontechvaccineinchildrenaged511yearsauthorsreplytocorrespondence
AT tamburromanuela safetyofmrnabnt162b2covid19pfizerbiontechvaccineinchildrenaged511yearsauthorsreplytocorrespondence

Ejemplares similares